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Predicting the likelihood of a clinical outcome using bio-
markers during the course of a cancer immunotherapy can
be a powerful tool for time-sensitive decision making on
personalized treatment options. In a clinical trial with the
survivin-targeting vaccine DPX-Survivac, we showed using
established methods (ELISpot/tetramer/flow cytometry)
that a high-dose of DPX-Survivac vaccine in combination
with low dose metronomic oral cyclophosphamide
(mCPA) induced much stronger immune responses in
ovarian cancer patients (cohort C, n=6) compared to vac-
cine alone (cohort A, n=6) or low dose vaccine with mCPA
(cohort B, n=6). Immune responses were detected ex vivo
in patients’ PBMCs particularly in cohort C, a reflection of
the magnitude of the immune responses generated by the
vaccine. We further analyzed the kinetics of various T cell
phenotypes of the CD4 and CD8 lineages, including
effector/ central memory T cells and late differentiated
CD8 T cells. We established a model for the sequential
appearance of polyfunctional T cells of the various pheno-
types and for the persistence of these cell types following
repeated immunizations with DPX-Survivac. In addition,
we explored a unique PCR-based ‘real-time’ method devel-
oped by Hitachi Chemical Research Center for analyzing
mRNA expression signatures that could be associated with
vaccine induced immune responses. For this, small quanti-
ties of fresh blood from immunized patients were directly
incubated with vaccine antigens and analyzed by qPCR at
pre- and one month post-immunization time points.
Among 9 immune response-related biomarkers tested,
mRNA for molecules such as IFN-g, GM-CSF, TNF-a and
CXCL10 were detected de novo in the blood of four out of
four subjects tested among six patients from cohort C at
one month following the third vaccination. These results
are in keeping with the establishment of stronger immune
responses and the kinetics of vaccine-induced memory/
effector T cells observed at this time point in patients
receiving the combination of DPX-Survivac and cyclopho-
sphamide. Taken together, these findings provide a frame-
work for identifying a potential immune response signature
soon after initiation of the vaccine therapy. We will deter-
mine whether this immune response signature is predictive
of clinical activity in a planned randomized phase 2 trial.
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